{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:56:05Z","timestamp":1791251765233,"version":"4.1.0"},"reference-count":104,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":3110,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:p>Ibandronate is a potent nitrogen\u2010containing bisphosphonate. It has a strong affinity for bone mineral and potently inhibits osteoclast\u2010mediated bone resorption. Ibandronate is effective for the treatment of hypercalcemia of malignancy, metastatic bone disease, postmenopausal osteoporosis, corticosteroid\u2010induced osteoporosis, and Paget's disease. Oral ibandronate is rapidly absorbed (t<jats:sub>max<\/jats:sub> &lt; 1 hour), with a low bioavailability (0.63%) that is further reduced (by up to 90%) in the presence of food. Ibandronate has a wide therapeutic index and is not metabolized and, therefore, has a low potential for drug interactions. Given its metabolic stability, ibandronate is eliminated from the blood by partitioning into bone (40%\u201050%) and through renal clearance (CL<jats:sub>R<\/jats:sub> \u223c60 mL\/min). The CL<jats:sub>R<\/jats:sub> of ibandronate is linearly related to creatinine clearance. The sequestration of ibandronate in bone (V<jats:sub>D<\/jats:sub> &gt; 90 L) results in a multiphasic elimination (t<jats:sub>1\/2<\/jats:sub> range \u223c10\u201360 hours), characterized by the slow release of ibandronate from the bone compartment. The potency of ibandronate and its sequestration into bone allow ibandronate to be developed as oral and intravenous injection formulations that can be administered with convenient extended between\u2010dose intervals.<\/jats:p>","DOI":"10.1177\/0091270004267594","type":"journal-article","created":{"date-parts":[[2004,8,18]],"date-time":"2004-08-18T19:37:50Z","timestamp":1092857870000},"page":"951-965","source":"Crossref","is-referenced-by-count":126,"title":["Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update"],"prefix":"10.1002","volume":"44","author":[{"given":"Joanne","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frieder","family":"Bauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00004164"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(99)00116-7"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12 <2961::AID-CNCR12>3.0.CO;2-L"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.19.1.0325"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3890"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12 <3054::AID-CNCR23>3.0.CO;2-Z"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s005200100292"},{"key":"e_1_2_8_9_2","volume-title":"Bisphosphonates in Bone Disease: From the Laboratory to the Patient","author":"Fleisch H","year":"1995"},{"key":"e_1_2_8_10_2","first-page":"504","article-title":"Bisphosphonates in the treatment of osteoporosis: principles and efficacy","volume":"151","author":"Papapoulos SE","year":"2000","journal-title":"Ann Med Intern"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08827-X"},{"key":"e_1_2_8_12_2","first-page":"M406","article-title":"Compliance with alendronate treatment in an osteoporosis clinic","volume":"15","author":"Lombas C","year":"2000","journal-title":"J Bone Miner Res"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80085-6"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.268"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.48"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014795216669"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg367"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008386501738"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(96)00229-3"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00249-0"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.10.1871"},{"key":"e_1_2_8_22_2","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","author":"Chesnut C","journal-title":"J Bone Miner Res;"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-022029"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1425-0"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg205"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(99)00072-1"},{"key":"e_1_2_8_27_2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/clinchem\/46.5.684","article-title":"Short\u2010 and long\u2010term effects of ibandronate treatment on bone turnover in Paget's disease of bone","volume":"46","author":"Woitge HW","year":"2000","journal-title":"Clin Chem"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650060915"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1612-7"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01174.x"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)90005-1"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03339822"},{"key":"e_1_2_8_33_2","first-page":"28","article-title":"Osteoporosis: efficacy and safety of a bisphosphonate dosed once weekly","volume":"56","author":"Baran D","year":"2001","journal-title":"Geriatrics"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-2011-8"},{"key":"e_1_2_8_35_2","article-title":"Efficacy and safety of ibandronate given once every 3 months","author":"Adami S","journal-title":"Bone"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.10.969"},{"key":"e_1_2_8_37_2","article-title":"Insufficiently dosed i.v. ibandronate injections are associated with suboptimal antifracture postmenopausal osteoporosis","author":"Recker RR","journal-title":"Bone"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957010-00011"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12 <2961::AID-CNCR12>3.0.CO;2-L"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650091206"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1998.13.4.581"},{"key":"e_1_2_8_42_2","first-page":"235","article-title":"Structure\u2010activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen\u2010containing bisphosphonates","volume":"296","author":"Dunford JE","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(92)80551-Z"},{"key":"e_1_2_8_44_2","first-page":"239","article-title":"Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy\u2010associated hypercalcemia","volume":"35","author":"Usui T","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04304.x"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01351831"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90245-7"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011024200280"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00259-6"},{"key":"e_1_2_8_50_2","first-page":"209a","article-title":"Population pharmacokinetics (PK) of Zometa [abstract 814]","volume":"19","author":"Berenson J","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127002762491316"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922007958"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00194339"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022008928"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02555856"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199410000-00010"},{"key":"e_1_2_8_57_2","first-page":"294","article-title":"Comparison of pharmacokinetics of clodronate after single and repeated doses","volume":"37","author":"Ylitalo P","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600831218"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00445-9"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90328-T"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(03)00300-4"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(00)00655-4"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011910517200"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867023369998"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(01)00665-2"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012470862-4\/50017-9"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1986.tb03254.x"},{"key":"e_1_2_8_68_2","first-page":"926","article-title":"Physiological disposition of alendronate, a potent anti\u2010osteolytic bisphosphonate, in laboratory animals","volume":"19","author":"Lin JH","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00035.x"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936050-00002"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(03)00033-4"},{"key":"e_1_2_8_72_2","first-page":"400","article-title":"Nonlinear kinetics of alendronate: plasma protein binding and bone uptake","volume":"22","author":"Lin JH","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_8_73_2","first-page":"A18","article-title":"Pharmacokinetics of ibandronate, a highly potent antiresorptive drug on bone metabolism in patients with multiple myeloma [abstract]","volume":"54","author":"Neugebauer G","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_8_74_2","first-page":"289","article-title":"Ibandronate: serum kinetics, tissue distribution and binding to bone following intravenous bolus injection [abstract P\u2010128]","volume":"70","author":"Bauss F","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008626026484"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161060-00010"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.10.1700"},{"key":"e_1_2_8_78_2","first-page":"S371","article-title":"Alendronate and risedronate have similar pharmacokinetic half\u2010lives when analysed over the same time interval","volume":"18","author":"Porras A","year":"2003","journal-title":"J Bone Miner Res"},{"key":"e_1_2_8_79_2","first-page":"2200","article-title":"Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats","volume":"29","author":"Bauss F","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_8_80_2","first-page":"473","article-title":"Effects of dose, sex and age on the disposition of alendronate, a potent anti\u2010osteolytic bisphosphonate, in rats","volume":"20","author":"Lin JH","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_8_81_2","first-page":"608","article-title":"Renal handling of alendronate in rats: an uncharacterized renal transport system","volume":"20","author":"Lin JH","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00135.x"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)91465-4"},{"key":"e_1_2_8_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-6009(91)90131-I"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.3109\/08860229409044906"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199614030-00003"},{"key":"e_1_2_8_87_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957010-00012"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00071.x"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-483X(03)00257-9"},{"key":"e_1_2_8_90_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650110506"},{"key":"e_1_2_8_91_2","first-page":"122a","article-title":"Influence of peak ibandronic acid concentrations after 6mg iv administration with shortened infusion time (15 and 30 minutes) on renal safety in man [abstract 486]","volume":"20","author":"Neugebauer G","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_8_92_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.12.2797"},{"key":"e_1_2_8_93_2","doi-asserted-by":"publisher","DOI":"10.1159\/000046123"},{"key":"e_1_2_8_94_2","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double\u2010blind, comparative trial","volume":"7","author":"Rosen LS","year":"2001","journal-title":"Cancer J"},{"key":"e_1_2_8_95_2","first-page":"20","article-title":"FDA panel endorses Zometa for bone metastases","volume":"2718","year":"2002","journal-title":"Scrip"},{"key":"e_1_2_8_96_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.7.1281"},{"key":"e_1_2_8_97_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1271530"},{"key":"e_1_2_8_98_2","unstructured":"BaussF KlingL WorthE BarrettJ:Drug\u2010drug interactions are unlikely with ibandronate. IOF World Congress on Osteoporosis2004(IOF WCO 2004) [accepted abstract]."},{"key":"e_1_2_8_99_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1409-0"},{"key":"e_1_2_8_100_2","first-page":"990","article-title":"The total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats","volume":"29","author":"Bauss F","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_8_101_2","first-page":"469","article-title":"Exploring clinical study design by computer simulation based on pharmacokinetic\/pharmacodynamic modelling","volume":"35","author":"Gieschke R","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_8_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03190058"},{"issue":"3","key":"e_1_2_8_103_2","first-page":"S23","article-title":"Exploring oral and intravenous ibandronate dosing regimens by clinical trial simulation [abstract P36]","volume":"13","author":"Gieschke R","year":"2002","journal-title":"Osteoporos Int"},{"key":"e_1_2_8_104_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.9.1662"},{"key":"e_1_2_8_105_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011807"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270004267594","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270004267594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:01:04Z","timestamp":1697108464000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270004267594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1177\/0091270004267594"],"URL":"https:\/\/doi.org\/10.1177\/0091270004267594","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}